I-Mab Announces Upcoming Participation at April Conferences
SHANGHAI, China, and ROCKVILLE, MD., April 06, 2020 (GLOBE NEWSWIRE) — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, today announced its participation in the following conferences in April. Management presentation details are as follows:
Solebury Trout Virtual Global Healthcare Conference
Presentation: Tuesday, April 7, 2020 at 12:30 p.m. ET
Presenter: Dr. Jingwu Zang, Founder, Honorary Chairman and DirectorFor more information, please visit: https://troutaccess.com/investor.php/c/Solebury_Trout_Virtual_Global_Healthcare_ConferenceNeedham Virtual Healthcare Conference
Presentation: Tuesday, April 14, 2020 at 9:20 – 10:00 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR DirectorOne-on-one meetings: April 14, 2020For more information, please contact conferences@needhamco.com or your Needham representative.About I-MabI-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. Company’s mission is to bring transformational medicines to patients through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. I-Mab has offices in China and the United States. For more information, please visit http://ir.i-mabbiopharma.com/.For more information, please contact:I-Mab
Jielun Zhu, CFO
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000Investor Inquiries:Burns McClellan, Inc. (Americas and Europe)
Steve Klass
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006The Piacente Group, Inc. (Asia)
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363Media Inquiries (Americas and Europe):Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
E-mail: rimai@burnsmc.com / rflamm@burnsmc.com
Office line: +1 212 213 0006
Solebury Trout Virtual Global Healthcare Conference
Presentation: Tuesday, April 7, 2020 at 12:30 p.m. ET
Presenter: Dr. Jingwu Zang, Founder, Honorary Chairman and DirectorFor more information, please visit: https://troutaccess.com/investor.php/c/Solebury_Trout_Virtual_Global_Healthcare_ConferenceNeedham Virtual Healthcare Conference
Presentation: Tuesday, April 14, 2020 at 9:20 – 10:00 a.m. ET
Presenters: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR DirectorOne-on-one meetings: April 14, 2020For more information, please contact conferences@needhamco.com or your Needham representative.About I-MabI-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. Company’s mission is to bring transformational medicines to patients through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to become a fully integrated end-to-end global biopharmaceutical company with cutting-edge discovery platforms, proven preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. I-Mab has offices in China and the United States. For more information, please visit http://ir.i-mabbiopharma.com/.For more information, please contact:I-Mab
Jielun Zhu, CFO
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000Investor Inquiries:Burns McClellan, Inc. (Americas and Europe)
Steve Klass
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006The Piacente Group, Inc. (Asia)
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363Media Inquiries (Americas and Europe):Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
E-mail: rimai@burnsmc.com / rflamm@burnsmc.com
Office line: +1 212 213 0006
